Briacell Therapeutics Corp (BCTX) Stock Price, Quote & News

Company Profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agree...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 921 1810

Fax: 604 921 1898

Website: briacell.com

Address:

Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

shonv May. 28 at 4:54 PM

$BCTX Saturday and Monday will be interesting...

0 · Reply

shonv May. 28 at 4:53 PM

$BCTX Go $BCTX Go....

0 · Reply

BHWinehouse May. 28 at 12:30 PM

$BCTX Worth repeating.

3 · Reply

shonv May. 28 at 3:26 AM

$BB Go $BB Go.... Another Canadian $BCTX . Keep an eye. Very low float. Anytime can start fly. $BCTX ✔️ 6th straight positive DSMB review ✔️ No safety concerns ✔️ Phase 3 continues unchanged If a DSMB releases a highly positive report indicating that a drug is incredibly safe and highly effective (e.g., passing a major Phase 2 or Phase 3 trial milestone), it increases the asset's value. This success often triggers Big Pharma to approach the smaller biotech company for a buyout to secure the drug before it goes to market. Conversely, a negative DSMB report (indicating poor efficacy or unacceptable toxicity) typically tanks the asset's value and deters buyouts

2 · Reply

shonv May. 28 at 12:55 AM

$BCTX Abstract Title: Monitoring blood-based biomarkers as early predictors of progression-free survival in a randomized Bria-ABC Phase 3 trial for advanced metastatic breast cancer: An ongoing analysis. Session Type/Title: Poster Session - Developmental Therapeutics—Immunotherapy Poster Board: 442 Date and Time: May 30, 2026, 1:30 PM-4:30 PM CDT **** Hopefully Good days r coming...

0 · Reply

shonv May. 27 at 8:46 PM

$BCTX Green is beautiful

2 · Reply

AshleySchaeffer_BMW May. 27 at 8:40 PM

$BCTX what are the strike prices on the warrants?

1 · Reply

2maligators May. 27 at 7:19 PM

$BCTX

0 · Reply

shonv May. 27 at 7:11 PM

$BCTX Go... $BCTX Go....

0 · Reply

dlev18 May. 27 at 5:34 PM

$BCTX one day🙏

0 · Reply

BriaCell (BCTX) Receives Positive Update from Data Safety Monitoring Board

2026-05-26T13:05:39.000Z - 2 days ago

BriaCell receives recommendation for DSMB for Phase 3 Bria-ABC study

Tue, 26 May 2026 07:30:00 -0400 - 2 days ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

2026-05-22T13:27:19.000Z - 6 days ago

BriaCell (BCTX) Unveils Key Clinical Data at ASCO Annual Meeting 2026

2026-05-22T11:49:02.000Z - 6 days ago

BriaCell announces data from Bria-IMT at ASCO 2026

Fri, 22 May 2026 07:30:00 -0400 - 6 days ago

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026

Fri, 15 May 2026 07:30:00 -0400 - 13 days ago

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™

2026-05-14T15:31:53.000Z - 14 days ago

BriaCell (BCTX) Completes Manufacturing for New Prostate Cancer Treatment

Thu, 14 May 2026 07:30:00 -0400 - 14 days ago

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer

2026-05-13T16:39:28.000Z - 15 days ago

BriaCell (BCTX) Expands Clinical Trial Network for Advanced Breast Cancer Treatment

2026-05-13T14:41:55.000Z - 15 days ago

BriaCell adds Penn Medicine as Phase 3 breast cancer study site

Wed, 13 May 2026 07:30:00 -0400 - 15 days ago

BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

Tue, 12 May 2026 07:30:00 -0400 - 16 days ago

BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients

Thu, 07 May 2026 07:30:00 -0400 - 21 days ago

BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

2026-05-07T04:03:56.000Z - 21 days ago

BriaCell receives FDA clearance to initiate Bria-BRES+ trial

Wed, 06 May 2026 07:30:00 -0400 - 22 days ago

BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer

Mon, 27 Apr 2026 07:30:00 -0400 - 4 weeks ago

BriaCell Announces Six Clinical Data Presentations at ASCO 2026

2026-04-21T13:28:43.000Z - 5 weeks ago

BriaCell (BCTX) Showcases Promising Data at AACR Annual Meeting

2026-04-21T11:54:23.000Z - 5 weeks ago

BriaCell presents anti-cancer activity of Bria-OTS

Tue, 21 Apr 2026 07:30:00 -0400 - 5 weeks ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models

2026-04-20T13:32:04.000Z - 5 weeks ago

BriaCell (BCTX) Showcases Positive Clinical Data at AACR Annual Meeting

2026-04-20T11:41:56.000Z - 5 weeks ago

BriaCell presents Phase 3 quality of life, Phase 2 biomarker data at AACR

Mon, 20 Apr 2026 07:30:00 -0400 - 5 weeks ago

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

Tue, 31 Mar 2026 16:05:00 -0400 - 2 months ago

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

2026-03-18T13:30:56.000Z - 2 months ago

BriaCell (BCTX) to Reveal Key Findings at 2026 AACR Annual Meeting

2026-03-18T11:42:55.000Z - 2 months ago

BriaCell to present four posters at the 2026 AACR

Wed, 18 Mar 2026 07:30:00 -0400 - 2 months ago

BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

Tue, 10 Mar 2026 07:30:00 -0400 - 2 months ago

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

Thu, 05 Mar 2026 16:04:00 -0500 - 2 months ago

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

2026-02-18T22:51:30.000Z - 3 months ago

BriaCell (BCTX) Expands Biologic Cancer Treatments Through New Agreement

2026-02-18T22:35:25.000Z - 3 months ago

BriaPro to purchase BriaCell’s license to develop, commercialize sCD80

Wed, 18 Feb 2026 17:30:00 -0500 - 3 months ago

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

2026-02-17T12:40:59.000Z - 3 months ago

BriaCell receives positive recommendation from DSMB for Phase 3 Bria-ABC study

Tue, 17 Feb 2026 07:30:00 -0500 - 3 months ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

2026-01-28T13:30:56.000Z - 4 months ago

BriaCell Therapeutics (BCTX) Shows Promising Results in Metastatic Breast Cancer Treatment

2026-01-28T12:40:40.000Z - 4 months ago

BriaCell says patient images show regression, resolution of metastsized tumors

Wed, 28 Jan 2026 07:30:00 -0500 - 4 months ago

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

2026-01-27T13:32:37.000Z - 4 months ago

BriaCell (BCTX) Reports Promising Phase 2 Survival Data

2026-01-27T12:41:04.000Z - 4 months ago

BriaCell extends 18-47 month survival in Phase 2 metastatic breast cancer

Tue, 27 Jan 2026 07:30:00 -0500 - 4 months ago

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

2026-01-19T16:00:45.000Z - 4 months ago

Is the Market Bullish or Bearish on BriaCell Therapeutics Corp?

2026-01-16T13:58:57.000Z - 4 months ago

Weekly Buzz: LYRA Slashes Jobs; FDA Okays FBIO's ZYCUBO; BSX To Acquire PEN; BCTX On Watch

Thu, 15 Jan 2026 16:05:00 -0500 - 4 months ago

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

2026-01-14T11:36:30.000Z - 4 months ago

What's Going On With BriaCell Therapeutics Stock Wednesday?

2026-01-14T11:19:44.000Z - 4 months ago

BriaCell Plunges On Pricing Announcement Of $30Mln Public Offering

2026-01-14T10:55:53.000Z - 4 months ago

BriaCell (BCTX) Unveils $30M Public Offering, Stock Dips 9.7%

2026-01-14T06:56:44.000Z - 4 months ago

BriaCell Therapeutics (BCTX) Launches $30M Public Offering

Tue, 13 Jan 2026 21:00:00 -0500 - 4 months ago

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

2026-01-13T20:32:32.000Z - 4 months ago

BCTX Surges On Positive Clinical Response In Metastatic Cancer Immunotherapy Study

2026-01-13T14:41:11.000Z - 4 months ago

BriaCell Therapeutics trading resumes

2026-01-13T14:35:29.000Z - 4 months ago

Market Cap	24.80M
Revenue (ttm)	0.00
Net Income (ttm)	-26.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	216,000
Avg Vol	211,374
Day's Range	N/A - N/A
Shares Out	7.25M
Stochastic %K	48%
Beta	1.26
Analysts	Strong Buy
Price Target	$40.00